Ro 61-8048, kynurenine 3-monooxygenase (KMO) inhibitor

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Kynurenine 3-monooxygenase (KMO) also known as kynurenine 3-hydroxylase is an enzyme that plays a mechanical role in the kynurenine pathway. This enzyme catalyzes the conversion of L-kynurenine to 3-hydroxykynurenine. KMO has a molecular mass of approximately 55 kDa. It is primarily expressed in the liver and kidney tissues but can also be found in other organs at lower levels. The structure of KMO contains a flavin adenine dinucleotide (FAD) binding domain which is essential for its oxidoreductase activity.

Biological function summary

KMO participates in the degradation of tryptophan significantly impacting the biosynthesis of nicotinamide adenine dinucleotide (NAD+). KMO is not known to be part of any protein complexes but its enzymatic activity is important for the production of downstream metabolites that influence various physiological processes. This activity affects immune response neurogenesis and energy metabolism highlighting its role in maintaining metabolic balance.

Pathways

KMO is an integral component of the kynurenine pathway which is critical for tryptophan catabolism. It associates closely with other enzymes like kynureninase and kynurenine aminotransferase. KMO exerts its function by regulating the levels of neuroactive and immunoactive metabolites in the brain and peripheral tissues. Through its role in the kynurenine pathway KMO influences cellular signaling and energy production connecting to broader metabolic pathways.

Associated diseases and disorders

KMO plays a significant role in neurodegenerative diseases such as Alzheimer's and Huntington's disease. Altered KMO activity leads to an imbalance of kynurenine pathway metabolites impacting neuronal health. The enzyme's dysfunction also associates with psychiatric disorders like schizophrenia. The relationship between KMO and other kynurenine pathway enzymes like kynurenine aminotransferase suggests that modulating its activity could present therapeutic opportunities for these conditions.